Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

pembrolizumab 29Cisplatin 18Nivolumab 14Carboplatin 14Paclitaxel 13Cyclophosphamide 13Radiation 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Magnetic Resonance Spectroscopy 9Cytarabine 9Vincristine 8Radiosurgery 8Docetaxel 8Bevacizumab 8Pemetrexed 7Metformin 7Leucovorin 7Injections 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Letrozole 6Irinotecan 6Ipilimumab 6Gemcitabine 6Dexamethasone 6venetoclax 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × azeliragon × 30 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡